SG Americas Securities LLC Has $9.18 Million Position in Embecta Corp. $EMBC

Key Points

• SG Americas Securities LLC boosted its Embecta stake by 138.4% in the first quarter, ending with 1,038,948 shares valued at about $9.18 million.
• Wall Street sentiment on Embecta has weakened, with multiple firms cutting ratings; the stock now carries a consensus “Strong Sell” and an average price target of $11.00.
• Embecta reported weaker-than-expected Q2 results, missing EPS and revenue estimates, and the company is now facing multiple securities class action lawsuits tied to alleged disclosure issues and a prior stock drop.

SG Americas Securities LLC increased its position in shares of Embecta Corp. (NASDAQ:EMBC - Free Report) by 138.4% in the first quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 1,038,948 shares of the company's stock after buying an additional 603,106 shares during the quarter. SG Americas Securities LLC owned 1.75% of Embecta worth $9,184,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Baron Wealth Management LLC acquired a new position in Embecta during the 1st quarter worth approximately $251,000. Rockefeller Capital Management L.P. raised its holdings in shares of Embecta by 25.0% in the fourth quarter. Rockefeller Capital Management L.P. now owns 344,544 shares of the company's stock valued at $4,093,000 after purchasing an additional 68,925 shares during the last quarter. Alpine Global Management LLC bought a new stake in shares of Embecta in the fourth quarter worth $178,000. River Road Asset Management LLC lifted its position in shares of Embecta by 5.3% in the fourth quarter. River Road Asset Management LLC now owns 3,416,401 shares of the company's stock worth $40,587,000 after purchasing an additional 171,194 shares in the last quarter. Finally, Pacer Advisors Inc. boosted its holdings in Embecta by 49.3% during the fourth quarter. Pacer Advisors Inc. now owns 16,526 shares of the company's stock worth $196,000 after purchasing an additional 5,460 shares during the last quarter. Institutional investors and hedge funds own 93.83% of the company's stock.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on EMBC. BTIG Research lowered shares of Embecta from a "buy" rating to a "neutral" rating in a research note on Tuesday, May 5th. Weiss Ratings downgraded shares of Embecta from a "hold (c-)" rating to a "sell (d+)" rating in a research note on Wednesday, May 6th. Mizuho decreased their price objective on Embecta from $12.00 to $5.00 and set a "neutral" rating for the company in a report on Wednesday, May 6th. Wall Street Zen downgraded Embecta from a "strong-buy" rating to a "hold" rating in a research report on Saturday, May 9th. Finally, Zacks Research downgraded Embecta from a "hold" rating to a "strong sell" rating in a research report on Friday, May 8th. Two investment analysts have rated the stock with a Hold rating and three have given a Sell rating to the company's stock. Based on data from MarketBeat, the company currently has a consensus rating of "Strong Sell" and an average price target of $11.00.

Key Headlines Impacting Embecta

Here are the key news stories impacting Embecta this week:

• Neutral Sentiment: Multiple law firms issued class action notices and lead-plaintiff deadline reminders for Embecta investors, keeping the stock in the news and drawing attention to the pending securities litigation. Article: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Embecta Corp. and Encourages Investors to Contact the Firm
• Neutral Sentiment: The lawsuits allege Embecta violated federal securities laws by concealing competitive threats and overstating the strength of its product category during the class period from November 25, 2025 through May 4, 2026. Article: Embecta Corp. (EMBC) Faces Securities Class Action for Allegedly Concealing Competitive Threats to Pen Needle Business -- HBSS
• Negative Sentiment: The legal actions highlight a prior stock plunge tied to Embecta’s disappointing Q2 2026 earnings and allegations that management’s earlier narrative conflicted with the results, reinforcing concerns about growth and execution. Article: EMBC Fraud Alert: Embecta Investors Sue for Recovery in Securities Fraud Class Action after 57% Stock Drop – Investors Notified to Contact BFA Law

Embecta Trading Up 12.0%

NASDAQ:EMBC opened at $3.48 on Friday. The stock has a market capitalization of $206.65 million, a PE ratio of 1.83 and a beta of 0.83. Embecta Corp. has a 1-year low of $2.77 and a 1-year high of $15.55. The firm has a fifty day simple moving average of $4.58 and a 200 day simple moving average of $8.47.

Embecta (NASDAQ:EMBC - Get Free Report) last announced its quarterly earnings results on Tuesday, May 5th. The company reported $0.27 EPS for the quarter, missing analysts' consensus estimates of $0.42 by ($0.15). Embecta had a net margin of 10.73% and a negative return on equity of 23.96%. The firm had revenue of $221.80 million during the quarter, compared to analyst estimates of $235.67 million. During the same quarter in the prior year, the business earned $0.70 EPS. The business's revenue was down 14.4% compared to the same quarter last year. Embecta has set its FY 2026 guidance at 1.550-1.75 EPS. On average, equities analysts predict that Embecta Corp. will post 1.62 earnings per share for the current fiscal year.

Embecta Cuts Dividend

The firm also recently declared a quarterly dividend, which was paid on Monday, June 15th. Investors of record on Thursday, May 28th were issued a dividend of $0.01 per share. The ex-dividend date was Thursday, May 28th. This represents a $0.04 dividend on an annualized basis and a yield of 1.1%. Embecta's dividend payout ratio (DPR) is presently 2.11%.

About Embecta

Embecta Corp NASDAQ: EMBC is a pure-play diabetes care company that was spun off from Becton, Dickinson and Company on July 1, 2021. Headquartered in Franklin Lakes, New Jersey, Embecta focuses exclusively on the development, manufacturing and commercialization of products that enable insulin delivery and blood glucose monitoring for people with diabetes.

The company’s product portfolio includes insulin infusion sets, durable and patch pumps, pen needles, infusion tubing, blood glucose test strips, lancets and lancing devices.

Want to see what other hedge funds are holding EMBC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Embecta Corp. (NASDAQ:EMBC - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.